A dedicated consortium comprised of the École Polytechnique Fédérale de Lausanne (EPFL), the University of Geneva (UNIGE), Dr. Hansjörg Wyss and the Bertarelli family has developed a project to convert part of the former Merck Serono site in Geneva, Switzerland, into a multi-development facility.
The project, Campus Biotech, will be a center of excellence in healthcare, biotechnology and life sciences, and will renew the vitality and competitiveness of this important sector in the Lake Geneva Region.
After Merck Serono's announcement to close its Geneva headquarters last summer, the Secheron complex was put on the market in July. On November 29, the deadline for offers, an offer was lodged by Campus Biotech, a company created by Hansjörg Wyss and Ernesto Bertarelli, in the context of a joint project with the EPFL and the University of Geneva.
The project plans for the founding of a "Wyss Institute" similar to the one that was created at Harvard University. The objective of this institute will be to support the activities of the research groups of the EPFL, the University of Geneva and potentially other academic institutions. A hub for innovation and applied research, the Institute will create approximately 10 new UNIGE and EPFL laboratories (research chairs) dedicated to studying areas such as immunoengineering, neuroengineering and regenerative engineering. The Wyss Foundation will endow the project with an initial capital of up to $134 million over six years, creating employment for 120 to 150 people.
If the purchase offer on the Secheron complex is accepted, it will provide the perfect site for the newly-formed Wyss Institute. Part of the building will be rented by the EPFL and UNIGE to provide the necessary 8,000 square meters of laboratory space. Strategically positioned within the Metropole lémanique, the Institute will form part of the EPFL and UNIGE's common strategy to develop scientific activities in the field of healthcare, with the aim of enhancing the transfer of technology from the academic to the industrial world. The research platforms will aim to clarify fundamental scientific problems such as transplant organ tolerance and the acceptance of new therapies. Also planned is the development of neuroprosthetics, including cochlear implants, retinal and motor prosthetics and regeneration of cardiovascular, muscular and neuromuscular tissue.
Based on a private-public partnership model, the project could progress rapidly thanks to its guaranteed and flexible financing. In addition to reinforcing the region's reputation as an international leader in biotechnology, it would reestablish the Secheron quarter as a hub for world-class research and innovation. The addition of other economic activity within the remaining space at Secheron is currently under study.
"This bid is an exciting and important opportunity to energize the future of the biotech and life sciences sector in the Lake Geneva region,” said Stefan Meister, COO of the Bertarelli family's joint business enterprise, Waypoint. “It is a complex project and opportunities of this sort can be fragile at the start, but the partners are confident it can be delivered effectively if the acquisition of the site is successful. It shows what the public and private sectors can do if given a challenge, and we look forward to making more progress in the coming weeks."